

Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection

NCT05709184

Status	RECRUITING
Phase	Not Applicable
Sponsor	Rambam Health Care Campus
Enrollment	196 participants

Key Eligibility Criteria

Inclusion (4)

- Consenting adults e18 years old with non-fulminant primary CDI.
- Both non-severe and severe patients will be included.
- Primary CDI (pCDI) will be defined as the patient's first event of CDI in the past 6 months: New-onset diarrhea (e3 unformed bowel movements (UBM) per day for more than 24 hours) and laboratory detection of toxigenic C. difficile in feces.
- A positive CD stool sample will be defined per study center according to international guidelines, with an obligatory positive toxin test to assure the presence of an active toxigenic CD strain.

Exclusion (19)

- Patients who cannot provide informed consent and do not have a legal guardian;
- History of CDI 6 months prior to screening
- Known presence of other stool pathogens known to cause diarrhea;
- Patients who cannot swallow;
- Background diagnosis of inflammatory bowel disease, irritable bowel syndrome (IBS), or any other chronic diarrheal disorder;
- ... and 14 more (see full listing online)

Locations (6 total)

University of Alberta, Edmonton, Canada
University of Debrecen, Debrecen, Hungary
Rambam Health Care Campus, Haifa, Israel
... and 3 more locations